Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity

Irina N. Gaisina, Werner Tueckmantel, Andrey Ugolkov, Sida Shen, Jessica Hoffen, Oleksii Dubrovskyi, Andrew Mazar, Renee A. Schoon, Daniel D Billadeau, Alan P. Kozikowski

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large number of proteins involved in cancer initiation and progression. The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compounds would avoid some of the undesirable side effects found with the first-generation inhibitors. A series of HDACIs previously reported by us were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells. In the present work, we show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth. Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells. We conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation. High or low selectivity: A new class of HDAC inhibitors bearing an isoxazole ring show high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly showing little potency in blocking cell growth. These results suggest that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. The highly selective HDAC6 inhibitors reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.

Original languageEnglish (US)
Pages (from-to)81-92
Number of pages12
JournalChemMedChem
Volume11
Issue number1
DOIs
StatePublished - Jan 5 2016

Fingerprint

Histone Deacetylases
Cytotoxicity
Cell growth
Cells
Isoxazoles
Immune system
Growth
Neoplasms
Protein Isoforms
Bearings (structural)
Immune System
Apoptosis
Histone Deacetylase Inhibitors
Cell Cycle Checkpoints
Pancreatic Neoplasms
Cell Line
Enzymes
Proteins

Keywords

  • HDAC6 selectivity
  • histone deacetylases
  • hydroxamic acids
  • immune activation
  • inhibitors
  • pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Gaisina, I. N., Tueckmantel, W., Ugolkov, A., Shen, S., Hoffen, J., Dubrovskyi, O., ... Kozikowski, A. P. (2016). Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity. ChemMedChem, 11(1), 81-92. https://doi.org/10.1002/cmdc.201500456

Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity. / Gaisina, Irina N.; Tueckmantel, Werner; Ugolkov, Andrey; Shen, Sida; Hoffen, Jessica; Dubrovskyi, Oleksii; Mazar, Andrew; Schoon, Renee A.; Billadeau, Daniel D; Kozikowski, Alan P.

In: ChemMedChem, Vol. 11, No. 1, 05.01.2016, p. 81-92.

Research output: Contribution to journalArticle

Gaisina, IN, Tueckmantel, W, Ugolkov, A, Shen, S, Hoffen, J, Dubrovskyi, O, Mazar, A, Schoon, RA, Billadeau, DD & Kozikowski, AP 2016, 'Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity', ChemMedChem, vol. 11, no. 1, pp. 81-92. https://doi.org/10.1002/cmdc.201500456
Gaisina IN, Tueckmantel W, Ugolkov A, Shen S, Hoffen J, Dubrovskyi O et al. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity. ChemMedChem. 2016 Jan 5;11(1):81-92. https://doi.org/10.1002/cmdc.201500456
Gaisina, Irina N. ; Tueckmantel, Werner ; Ugolkov, Andrey ; Shen, Sida ; Hoffen, Jessica ; Dubrovskyi, Oleksii ; Mazar, Andrew ; Schoon, Renee A. ; Billadeau, Daniel D ; Kozikowski, Alan P. / Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity. In: ChemMedChem. 2016 ; Vol. 11, No. 1. pp. 81-92.
@article{90c7903da3e943dabf8fb55f5ec97faf,
title = "Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity",
abstract = "The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large number of proteins involved in cancer initiation and progression. The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compounds would avoid some of the undesirable side effects found with the first-generation inhibitors. A series of HDACIs previously reported by us were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells. In the present work, we show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth. Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells. We conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation. High or low selectivity: A new class of HDAC inhibitors bearing an isoxazole ring show high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly showing little potency in blocking cell growth. These results suggest that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. The highly selective HDAC6 inhibitors reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.",
keywords = "HDAC6 selectivity, histone deacetylases, hydroxamic acids, immune activation, inhibitors, pancreatic cancer",
author = "Gaisina, {Irina N.} and Werner Tueckmantel and Andrey Ugolkov and Sida Shen and Jessica Hoffen and Oleksii Dubrovskyi and Andrew Mazar and Schoon, {Renee A.} and Billadeau, {Daniel D} and Kozikowski, {Alan P.}",
year = "2016",
month = "1",
day = "5",
doi = "10.1002/cmdc.201500456",
language = "English (US)",
volume = "11",
pages = "81--92",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity

AU - Gaisina, Irina N.

AU - Tueckmantel, Werner

AU - Ugolkov, Andrey

AU - Shen, Sida

AU - Hoffen, Jessica

AU - Dubrovskyi, Oleksii

AU - Mazar, Andrew

AU - Schoon, Renee A.

AU - Billadeau, Daniel D

AU - Kozikowski, Alan P.

PY - 2016/1/5

Y1 - 2016/1/5

N2 - The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large number of proteins involved in cancer initiation and progression. The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compounds would avoid some of the undesirable side effects found with the first-generation inhibitors. A series of HDACIs previously reported by us were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells. In the present work, we show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth. Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells. We conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation. High or low selectivity: A new class of HDAC inhibitors bearing an isoxazole ring show high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly showing little potency in blocking cell growth. These results suggest that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. The highly selective HDAC6 inhibitors reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.

AB - The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large number of proteins involved in cancer initiation and progression. The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compounds would avoid some of the undesirable side effects found with the first-generation inhibitors. A series of HDACIs previously reported by us were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells. In the present work, we show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth. Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells. We conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation. High or low selectivity: A new class of HDAC inhibitors bearing an isoxazole ring show high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly showing little potency in blocking cell growth. These results suggest that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required. The highly selective HDAC6 inhibitors reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.

KW - HDAC6 selectivity

KW - histone deacetylases

KW - hydroxamic acids

KW - immune activation

KW - inhibitors

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84954027655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954027655&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201500456

DO - 10.1002/cmdc.201500456

M3 - Article

C2 - 26592932

AN - SCOPUS:84954027655

VL - 11

SP - 81

EP - 92

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 1

ER -